Literature DB >> 20504925

In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.

Kurt I Kamrud1, V McNeil Coffield, Gary Owens, Christin Goodman, Kim Alterson, Max Custer, Michael A Murphy, Whitney Lewis, Sarah Timberlake, Elizabeth K Wansley, Peter Berglund, Jonathan Smith.   

Abstract

Alphavirus-based replicon vector systems (family Togaviridae) have been developed as expression vectors with demonstrated potential in vaccine development against both infectious diseases and cancer. The single-cycle nature of virus-like replicon particles (VRP), generated by supplying the structural proteins from separate replicable helper RNAs, is an attractive safety component of these systems. MicroRNAs (miRNAs) have emerged as important cellular RNA regulation elements. Recently, miRNAs have been employed as a mechanism to attenuate or restrict cellular tropism of replication-competent viruses, such as oncolytic adenoviruses, vesicular stomatitis virus, and picornaviruses as well as nonreplicating lentiviral and adenoviral vectors. Here, we describe the incorporation of miRNA-specific target sequences into replicable alphavirus helper RNAs that are used in trans to provide the structural proteins required for VRP production. VRP were found to be efficiently produced using miRNA-targeted helper RNAs if miRNA-specific inhibitors were introduced into cells during VRP production. In the absence of such inhibitors, cellular miRNAs were capable of downregulating helper RNA replication in vitro. When miRNA targets were incorporated into a replicon RNA, cellular miRNAs were capable of downregulating replicon RNA replication upon delivery of VRP into animals, demonstrating activity in vivo. These data provide the first example of miRNA-specific repression of alphavirus replicon and helper RNA replication and demonstrate the feasibility of miRNA targeting of expression vector helper functions that are provided in trans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20504925      PMCID: PMC2897628          DOI: 10.1128/JVI.00310-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  80 in total

1.  RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

Authors:  P D Zamore; T Tuschl; P A Sharp; D P Bartel
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  Identification of novel genes coding for small expressed RNAs.

Authors:  M Lagos-Quintana; R Rauhut; W Lendeckel; T Tuschl
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

3.  A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.

Authors:  G Hutvágner; J McLachlan; A E Pasquinelli; E Bálint; T Tuschl; P D Zamore
Journal:  Science       Date:  2001-07-12       Impact factor: 47.728

4.  Transmission of replication-defective Sindbis helper vectors encoding capsid and envelope proteins.

Authors:  X Lu; J Silver
Journal:  J Virol Methods       Date:  2001-01       Impact factor: 2.014

5.  Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans.

Authors:  R F Ketting; S E Fischer; E Bernstein; T Sijen; G J Hannon; R H Plasterk
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

6.  Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

Authors:  David I Bernstein; Elizabeth A Reap; Kevin Katen; Aubrey Watson; Kaitlin Smith; Pamela Norberg; Robert A Olmsted; Amy Hoeper; John Morris; Sarah Negri; Maureen F Maughan; Jeffrey D Chulay
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

7.  Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing.

Authors:  A Grishok; A E Pasquinelli; D Conte; N Li; S Parrish; I Ha; D L Baillie; A Fire; G Ruvkun; C C Mello
Journal:  Cell       Date:  2001-07-13       Impact factor: 41.582

8.  Biogenesis of the Semliki Forest virus RNA replication complex.

Authors:  P Kujala; A Ikäheimonen; N Ehsani; H Vihinen; P Auvinen; L Kääriäinen
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans.

Authors:  N C Lau; L P Lim; E G Weinstein; D P Bartel
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

10.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

View more
  11 in total

Review 1.  MicroRNA-regulated viral vectors for gene therapy.

Authors:  Anja Geisler; Henry Fechner
Journal:  World J Exp Med       Date:  2016-05-20

2.  Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.

Authors:  Eugenio J Abente; Daniela S Rajao; Phillip C Gauger; Amy L Vincent
Journal:  Vaccine       Date:  2019-02-02       Impact factor: 3.641

3.  Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting.

Authors:  Erkko Ylösmäki; Miika Martikainen; Ari Hinkkanen; Kalle Saksela
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

4.  MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity.

Authors:  Ryan Cawood; Suet-Ling Wong; Ying Di; Dilair F Baban; Leonard W Seymour
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

5.  A vaccinia virus recombinant transcribing an alphavirus replicon and expressing alphavirus structural proteins leads to packaging of alphavirus infectious single cycle particles.

Authors:  Juana M Sánchez-Puig; María M Lorenzo; Rafael Blasco
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

Review 6.  Latest development on RNA-based drugs and vaccines.

Authors:  Kenneth Lundstrom
Journal:  Future Sci OA       Date:  2018-05-04

7.  Control of the rescue and replication of Semliki Forest virus recombinants by the insertion of miRNA target sequences.

Authors:  Kaspar Ratnik; Liane Viru; Andres Merits
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

Review 8.  Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles.

Authors:  Alicia Rodríguez-Gascón; Ana del Pozo-Rodríguez; María Ángeles Solinís
Journal:  Int J Nanomedicine       Date:  2014-04-10

Review 9.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2014-06-16       Impact factor: 5.048

Review 10.  Implications of MicroRNAs in Oncolytic Virotherapy.

Authors:  Xavier Bofill-De Ros; Maria Rovira-Rigau; Cristina Fillat
Journal:  Front Oncol       Date:  2017-07-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.